|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 19.95 USD | +0.30% |
|
-3.53% | -25.31% |
| 09-28 | Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041 | MT |
| 09-28 | Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.44B | |||||
| 74.16B | |||||
| 57.39B | |||||
| 47.64B | |||||
| 44.29B | - | - | - | - | - |
| 42.5B |
Select your edition
All financial news and data tailored to specific country editions
